Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MNOV – Medicinova Inc

MediciNova, Inc.
MNOV
$1.43
Name : MediciNova, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $71,130,912.00
EPSttm : -0.23
finviz dynamic chart for MNOV
MediciNova, Inc.
$1.43
7.92%
$0.105

Float Short %

0.27

Margin Of Safety %

Put/Call OI Ratio

0.03

EPS Next Q Diff

EPS Last/This Y

-0.27

EPS This/Next Y

0.12

Price

1.43

Target Price

7

Analyst Recom

1

Performance Q

-2.72

Relative Volume

2.87

Beta

0.35

Ticker: MNOV




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04MNOV1.250.010.0085
2025-07-07MNOV1.260.010.0085
2025-07-08MNOV1.250.010.0085
2025-07-09MNOV1.270.010.0085
2025-07-10MNOV1.2801N/AN/A0
2025-07-11MNOV1.2650.010.00135
2025-07-14MNOV1.280.010.00135
2025-07-15MNOV1.250.010.00135
2025-07-16MNOV1.2550.010.00135
2025-07-17MNOV1.270.010.00135
2025-07-18MNOV1.230.010.00135
2025-07-21MNOV1.2450.02999.9953
2025-07-22MNOV1.270.02999.9953
2025-07-23MNOV1.2550.040.0054
2025-07-24MNOV1.2450.040.0054
2025-07-25MNOV1.460.030.0068
2025-07-28MNOV1.4670.030.0069
2025-07-29MNOV1.320.030.0069
2025-07-30MNOV1.360.030.0069
2025-07-31MNOV1.310.030.0069
2025-08-01MNOV1.40.030.0069
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04MNOV1.25- - -0.50
2025-07-07MNOV1.27- - -0.50
2025-07-08MNOV1.25- - -0.50
2025-07-09MNOV1.27- - -0.50
2025-07-10MNOV1.27- - -0.50
2025-07-11MNOV1.27- - -0.50
2025-07-14MNOV1.28- - -0.50
2025-07-15MNOV1.23- - -0.50
2025-07-16MNOV1.25- - -0.50
2025-07-17MNOV1.23- - -0.50
2025-07-18MNOV1.22- - -0.50
2025-07-21MNOV1.26- - -0.50
2025-07-22MNOV1.26- - -0.50
2025-07-23MNOV1.26- - -0.50
2025-07-24MNOV1.24- - -0.50
2025-07-25MNOV1.46- - -0.50
2025-07-28MNOV1.48- - -0.50
2025-07-29MNOV1.33- - -0.50
2025-07-30MNOV1.35- - -0.50
2025-07-31MNOV1.33- - -0.50
2025-08-01MNOV1.43- - -0.50
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04MNOV0.00-0.550.35
2025-07-07MNOV0.00-0.550.35
2025-07-08MNOV0.00-0.550.35
2025-07-09MNOV0.00-0.550.35
2025-07-10MNOV0.00-0.550.35
2025-07-11MNOV0.00-0.550.36
2025-07-14MNOV0.00-0.550.36
2025-07-15MNOV0.00-0.550.36
2025-07-16MNOV0.00-0.550.36
2025-07-17MNOV0.00-0.550.36
2025-07-18MNOV0.00-0.550.36
2025-07-21MNOV0.00-0.550.36
2025-07-22MNOV0.00-0.550.36
2025-07-23MNOV0.00-0.550.36
2025-07-24MNOV0.00-0.550.36
2025-07-25MNOV0.00-0.550.27
2025-07-28MNOV0.00-0.550.27
2025-07-29MNOV0.00-0.550.27
2025-07-30MNOV0.00-0.550.27
2025-07-31MNOV0.00-0.550.27
2025-08-01MNOV0.00-0.550.27
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

Institutional Transactions

-0.55

Beta

0.35

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

11

Growth Score

19

Sentiment Score

71

Actual DrawDown %

86.8

Max Drawdown 5-Year %

-87.1

Target Price

7

P/E

Forward P/E

PEG

P/S

P/B

1.4

P/Free Cash Flow

EPS

-0.23

Average EPS Est. Cur. Y​

-0.5

EPS Next Y. (Est.)

-0.38

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

2.87

Return on Equity vs Sector %

-46.1

Return on Equity vs Industry %

-27.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

MediciNova, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 13
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
stock quote shares MNOV – Medicinova Inc Stock Price stock today
news today MNOV – Medicinova Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MNOV – Medicinova Inc yahoo finance google finance
stock history MNOV – Medicinova Inc invest stock market
stock prices MNOV premarket after hours
ticker MNOV fair value insiders trading